Transferrin-mediated targeting of bacteriophage HK97 nanoparticles into tumor cells

Nanomedicine

Volumn 6, Issue 1, 2011, Pages 55-68

  Huang, Rick K ^a,b   Steinmetz, Nicole F ^a,c,d   Fu, Chi Yu ^c   Manchester, Marianne ^c   Johnson, John E ^a,b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d Case Western Reserve University   (United States)

Author keywords

cancer; HK97; protein conjugation; targeted cellular entry; transferrin; viral nanoparticles

Indexed keywords

FLUORESCENT DYE; NANOPARTICLE; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; VIRAL NANOPARTICLE;

ARTICLE; BACTERIOPHAGE; BACTERIOPHAGE HK97; CANCER CELL CULTURE; CHEMICAL ENGINEERING; CONTROLLED STUDY; DRUG SPECIFICITY; DRUG TARGETING; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL;

BACTERIOPHAGES; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FLUORESCENT DYES; HELA CELLS; HUMANS; MUTATION; NANOPARTICLES; NEOPLASMS; RECEPTORS, TRANSFERRIN; SULFHYDRYL COMPOUNDS; TRANSFERRIN;

EID: 78650670099     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.99     Document Type: Article

References (57)

1. Hajitou A, Pasqualini R, Arap W: Vascular targeting: recent advances and therapeutic perspectives. Trends cardiovasc. Med. 16(3), 80-88 (2006).
2. Heath Jr, DME: Nanotechnology and cancer. Annu. Rev. Med. 59, 251-265 (2008).
3. Majoros IJ, Williams CR, Baker Jr: Current dendrimer applications in cancer diagnosis and therapy. Curr. Top. Med. Chem. 8(14), 1165-1179 (2008).
4. Manchester M, Singh P: Virus-based nanoparticles (VNPS): platform technologies for diagnostic imaging. Adv. Drug Deliv. Rev. 58(14), 1505-1522 (2006).
5. Soussan E, Cassel S, Blanzat M, Rico-Lattes I: Drug delivery by soft matter: matrix and vesicular carriers. Angew. Chem. Int. Ed. Engl. 48(2), 274-288 (2009).
6. Xing Y, Rao J: Quantum dot bioconjugates for in vitro diagnostics & in vivo imaging. Cancer Biomark. 4(6), 307-319 (2008).
7. Rae C, Koudelka KJ, Destito G, Estrada MN, Gonzalez MJ, Manchester M: Chemical addressability of ultraviolet-inactivated viral nanoparticles (VNPS). PLoS One 3(10), e3315 (2008).
8. Fischlechner M, Donath E: Viruses as building blocks for materials and devices. Angew. Chem. Int. Ed. Engl. 46(18), 3184-3193 (2007).
9. Choi VW, Mccarty DM, Samulski RJ: A AV hybrid serotypes: improved vectors for gene delivery. Curr. Gene Ther. 5(3), 299-310 (2005).
10. Cockrell AS, Kafri T: Gene delivery by lentivirus vectors. Mol. Biotechnol. 36(3), 184-204 (2007).
11. Douglas JT: Adenovirus-mediated gene delivery: an overview. Methods Mol. Biol. 246, 3-14 (2004).
12. Liepold L, Anderson S, Willits D et al.: Viral capsids as MRI contrast agents. Magn. Reson. Med. 58(5), 871-879 (2007).
13. Brown WL, Mastico RA, Wu M et al.: RNA bacteriophage capsid-mediated drug delivery and epitope presentation. Intervirology 45(4-6), 371-380 (2002).
14. Lewis JD, Destito G, Zijlstra A et al.: Viral nanoparticles as tools for intravital vascular imaging. Nat. Med. 12(3), 354-360 (2006).
15. Ren Y, Wong SM, Lim LY: Folic acid-conjugated protein cages of a plant virus: a novel delivery platform for doxorubicin. Bioconjug. Chem. 18(3), 836-843 (2007).
16. Singh P, Prasuhn D, Yeh RM et al.: Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo. J. Control. Release 120(1-2), 41-50 (2007).
17. Dhillon EK, Dhillon TS, Lai AN, Linn S: Host range, immunity and antigenic properties of lambdoid coliphage hk97 J. Gen. Virol. 50(1), 217-220 (1980).
18. Duda RL, Hempel J, Michel H, Shabanowitz J, Hunt D, Hendrix RW: Structural transitions during bacteriophage HK97 head assembly J. Mol. Biol. 247(4), 618-635 (1995).
19. Gan L, Conway JF, Firek BA et al.: Control of crosslinking by quaternary structure changes during bacteriophage HK97 maturation. Mol. Cell 14(5), 559-569 (2004).
20. Ross PD, Cheng N, Conway JF et al.: Crosslinking renders bacteriophage HK97 capsid maturation irreversible and effects an essential stabilization. EMBO J. 24(7), 1352-1363 (2005).
21. Loo L, Guenther RH, Lommel SA, Franzen S: Encapsidation of nanoparticles by red clover necrotic mosaic virus. J. Am. Chem. Soc. 129(36), 11111-11117 (2007).
22. Minten IJ, Hendriks LJ, Nolte RJ, Cornelissen JJ: Controlled encapsulation of multiple proteins in virus capsids. J. Am. Chem. Soc. 131(49), 17771-17773 (2009).
23. Duda RL, Martincic K, Hendrix RW: Genetic basis of bacteriophage HK97 prohead assembly J. Mol. Biol. 247(4), 636-647 (1995).
24. Duda RL, Martincic K, Xie Z, Hendrix RW: Bacteriophage HK97 head assembly. FEMS Microbiol Rev 17(1-2), 41-46 (1995).
25. Gertsman I, Gan L, Guttman M et al.: An unexpected twist in viral capsid maturation. Nature 458(7238), 646-650 (2009).
26. Wikoff WR, Liljas L, Duda RL, Tsuruta H, Hendrix RW, Johnson JE: Topologically linked protein rings in the bacteriophage HK97 capsid. Science 289(5487), 2129-2133 (2000).
27. Steinmetz NF, Evans DJ, Lomonossoff GP: Chemical introduction of reactive thiols into a viral nanoscaffold: a method that avoids virus aggregation. Chembiochem 8(10), 1131-1136 (2007).
28. Wang Q, Lin T, Johnson JE, Finn MG: Natural supramolecular building blocks: cysteine-added mutants of cowpea mosaic virus. Chem. Biol. 9(7), 813-819 (2002). (Pubitemid 34861158)
29. Qian ZM, Li H, Sun H, Ho K: Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 54(4), 561-587 (2002).
30. Agarwal A, Saraf S, Asthana A, Gupta U, Gajbhiye V, Jain NK: Ligand based dendritic systems for tumor targeting. Int. J. Pharm. 350(1-2), 3-13 (2008).
31. Inoue T, Cavanaugh PG, Steck PA, Brunner N, Nicolson GL: Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. J. Cell Physiol. 156(1), 212-217 (1993).
32. Bridges KR, Smith BR: Discordance between transferrin receptor expression and susceptibility to lysis by natural killer cells. J. Clin. Invest. 76(3), 913-918 (1985).
33. Faulk WP, Hsi BL, Stevens PJ: Transferrin and transferrin receptors in carcinoma of the breast. Lancet 2(8191), 390-392 (1980).
34. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY: Transferrin receptors in human tissues: Their distribution and possible clinical relevance. J. Clin. Pathol. 36(5), 539-545 (1983).
35. Huebers HA, Finch CA: The physiology of transferrin and transferrin receptors. Physiol. Rev. 67(2), 520-582 (1987).
36. Jiang YY, Liu C, Hong MH, Zhu SJ, Pei YY: Tumor cell targeting of transferrin-PEG-TNF-a conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation. Bioconjug. Chem. 18(1), 41-49 (2007).
37. Macgillivray RT, Mendez E, Shewale JG, Sinha SK, Lineback-Zins J, Brew K: The primary structure of human serum transferrin. The structures of seven cyanogen bromide fragments and the assembly of the complete structure. J. Biol. Chem. 258(6), 3543-3553 (1983).
38. Bewley MC, Tam BM, Grewal J et al.: X-ray crystallography and mass spectroscopy reveal that the N-lobe of human transferrin expressed in Pichia pastoris is folded correctly but is glycosylated on serine-32. Biochemistry 38(8), 2535-2541 (1999).
39. Chamow SM, Kogan TP, Peers DH, Hastings RC, Byrn RA, Ashkenazi A: Conjugation of soluble cd4 without loss of biological activity via a novel carbohydrate- directed cross-linking reagent. J. Biol. Chem. 267(22), 15916-15922 (1992).
40. Sen Gupta S, Kuzelka J, Singh P, Lewis WG, Manchester M, Finn MG: Accelerated bioorthogonal conjugation: a practical method for the ligation of diverse functional molecules to a polyvalent virus scaffold. Bioconjug. Chem. 16(6), 1572-1579 (2005).
41. Wu M, Brown WL, Stockley PG: Cell-specifc delivery of bacteriophage-encapsidated ricin a chain. Bioconjug. Chem. 6(5), 587-595 (1995).
42. Pettersen EF, Goddard TD, Huang CC et al.: UCSF Chimera - a visualization system for exploratory research and ana lysis. J. Comput. Chem. 25(13), 1605-1612 (2004).
43. Gonzalez MJ, Plummer EM, Rae CS, Manchester M: Interaction of cowpea mosaic virus (CPMV) nanoparticles with antigen presenting cells in vitro and in vivo. PLoS One 4(11), e7981 (2009).
44. Koudelka KJ, Destito G, Plummer EM, Trauger SA, Siuzdak G, Manchester M: Endothelial targeting of cowpea mosaic virus (CPMV) via surface vimentin. PLoS Pathog. 5(5), e1000417 (2009).
45. Shriver LP, Koudelka KJ, Manchester M: Viral nanoparticles associate with regions of infammation and blood brain barrier disruption during CNS infection. J. Neuroimmunol. 211(1-2), 66-72 (2009).
46. Steinmetz NF, Manchester M: Pegylated viral nanoparticles for biomedicine: the impact of PEG chain length on VNP cell interactions in vitro and ex vivo. Biomacromolecules 10(4), 784-792 (2009).
47. Steinmetz NF, Hong V, Spoerke ED et al.: Buckyballs meet viral nanoparticles: Candidates for biomedicine. J. Am. Chem. Soc. 131(47), 17093-17095 (2009).
48. Steinmetz NF, Mertens ME, Taurog RE et al.: Potato virus X as a novel platform for potential biomedical applications. Nano Lett. 10(1), 305-312 (2010).
49. Kaiser CR, Flenniken ML, Gillitzer E et al.: Biodistribution studies of protein cage nanoparticles demonstrate broad tissue distribution and rapid clearance in vivo. Int. J. Nanomedicine 2(4), 715-733 (2007).
50. Prasuhn De Jr, Singh P, Strable E, Brown S, Manchester M, Finn MG: Plasma clearance of bacteriophage qbeta particles as a function of surface charge. J. Am. Chem. Soc. 130(4), 1328-1334 (2008).
51. Thurber GM, Schmidt MM, Wittrup KD: Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv. Drug Deliv. Rev. 60, 1421-1434 (2008).
52. Li H, Qian ZM: Transferrin/transferrin receptor-mediated drug delivery. Med. Res. Rev. 22(3), 225-250 (2002).
53. Wright CS: Structural comparison of the two distinct sugar binding sites in wheat germ agglutinin isolectin II. J. Mol. Biol. 178(1), 91-104 (1984).
54. Kresse M, Wagner S, Pfefferer D, Lawaczeck R, Elste V, Semmler W: Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways. Magn. Reson. Med. 40(2), 236-242 (1998).
55. Qing Y, Shuo W, Zhihua W et al.: The in vitro antitumor effect and in vivo tumor-specifcity distribution of human- mouse chimeric antibody against transferrin receptor. Cancer Immunol. Immunother. 55(9), 1111-1121 (2006).
56. Sato Y, Yamauchi N, Takahashi M et al.: In vivo gene delivery to tumor cells by transferrin-streptavidin-DNA conjugate. FASEB J. 14(13), 2108-2118 (2000).
57. White S, Taetle R, Seligman PA, Rutherford M, Trowbridge IS: Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects. Cancer Res. 50(19), 6295-6301 (1990).